Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease


You May Also Like

OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial

REDWOOD CITY, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a ...

Athersys and Healios Announce Binding Letter of Intent to Expand MultiStem® Collaboration

Equity investment and binding letter of intent outlines expansion of Japan collaboration, including exclusive ...